pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Bispecific Antibody · news · pharmadog
← back to Bispecific Antibody
News · Bispecific Antibody
151
stories
18d
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
18d
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
23d
Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers
biospace
23d
Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor
endpoints
23d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
23d
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
fiercebiotech
25d
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
25d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
28d
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
28d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
28d
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
29d
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 17, 26
Jasper gets a lifeline in merger with immune drugmaker Kira
biopharma dive
Jul 6, 26
Cancer, immune drugmakers dominate VC funding so far in 2026
biopharma dive
Jul 1, 26
STAT+: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenes
stat
Jun 30, 26
AbbVie and Genmab's latest win brings Epkinly closer to label expansion
endpoints
Jun 30, 26
These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
biopharma dive
Jun 30, 26
STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk
stat
Jun 30, 26
STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
stat
Jun 29, 26
5 takeaways from STAT’s investigation into microhospital operator Nutex Health
stat
Jun 26, 26
On second try, Acadia drug gets nod from European regulators
biopharma dive
Jun 17, 26
Jazz zeroes in on next-gen T cell engagers with AbCellera deal
biopharma dive
Jun 15, 26
J&J multiple myeloma drug gains edge in earlier stage disease
biopharma dive
Jun 5, 26
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
biopharma dive
Jun 3, 26
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
biopharma dive
Jun 1, 26
RallyBio tries again for reverse merger, this time with Avenzo
biopharma dive
Jun 1, 26
STAT+: A turning point for pancreatic cancer patients
stat
May 29, 26
Bristol Myers unveils data for one of its next-gen blood cancer drugs
biopharma dive
May 19, 26
A migraine drugmaker heads to the public markets through reverse merger
biopharma dive
← prev
page 2 of 6
next →
